Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors
Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors
About this item
Full title
Author / Creator
Publisher
England: Future Medicine Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Future Medicine Ltd
Subjects
More information
Scope and Contents
Contents
Evaluate associations between clinical outcomes and SNPs in patients with well-differentiated pancreatic neuroendocrine tumors receiving sunitinib.
Kaplan–Meier and Cox proportional hazards models were used to analyze the association between SNPs and survival outcomes using data from a sunitinib Phase IV (genotyped, n = 56) study. Fisher’s exact...
Alternative Titles
Full title
Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2232019089
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2232019089
Other Identifiers
ISSN
1479-6694
E-ISSN
1744-8301
DOI
10.2217/fon-2018-0934
